EasySep® Human CD19 Positive Selection Kit

Procedures and instruction manuals:

•  PRODUCT INFORMATION SHEET - 18054, Lot# All:28511-PIS_2_2_0.pdf
•  PRODUCT INFORMATION SHEET - 18054RF, Lot# All:28511-PIS_2_2_0.pdf

Educational resources:

•  VIDEO: EasySep®: Powerful Immunomagnetic Isolation of Virtually Any Cell Type
•  WEBINAR: Cell Separation Solutions for HLA and Chimerism Analysis
•  VIDEO: The EasySep® Pour-off: A Simple and Effective Way to Isolate Cells
•  VIDEO: EasySep®: Powerful Immunomagnetic Isolation of Virtually Any Cell Type
•  VIDEO: HetaSep™: A Guide to Isolating Nucleated Cells from Whole Blood
•  BROCHURE: Cell Separation Products for HLA Analysis
•  BROCHURE: RoboSep®: Solutions for HIV Research
•  BROCHURE: Cell Separation Equipment & Products
•  BROCHURE: Cell Separation for Autoimmunity Research
•  BROCHURE: Ready Sep Go – Cell Separation In As Little As 25 Minutes
•  VIDEO: The EasySep® MultiStand: Four Samples, Four Separations, One Pour-off
•  BROCHURE: Customized Cell Isolation: Flexible Cell Isolation Designed for you and your Research
•  VIDEO: RoboSep® Product Tour
•  VIDEO: How to Isolate Mononuclear Cells from Whole Blood by Density Gradient Centrifugation
•  VIDEO: RoboSep® Sneak Preview
•  BROCHURE: Fast and Easy Isolation of B Cells
•  BROCHURE: Fully Automated, High Purity Cell Isolation for Chimerism Labs
•  WALLCHART: Frequencies of Cell Types in Human Peripheral Blood Wallchart

MSDS:

•  18150_18150H-MSDS.pdf
•  18014C.2_18054C.2-MSDS.pdf

FAQS:

• 
  HOW EASYSEP™ WORKS
  
  
  • Q. CAN EASYSEP™ BE USED FOR EITHER POSITIVE OR NEGATIVE SELECTION?
    A. Yes. The EasySep™ kits use either a negative selection approach by targeting and removing unwanted cells or a positive selection approach targeting desired cells. Depletion kits are also available for the removal of cells with a specific undesired marker (e.g. GlyA).
  • Q. HOW DOES THE SEPARATION WORK?
    A. Magnetic particles are crosslinked to cells using Tetrameric Antibody Complexes (TAC). When placed in the EasySep™ Magnet, labeled cells migrate to the wall of the tube. The unlabeled cells are then poured off into a separate fraction.
  • Q. WHICH COLUMNS DO I USE?
    A. The EasySep™ procedure is column-free. That's right - no columns!
  • Q. HOW CAN I ANALYZE THE PURITY OF MY ENRICHED SAMPLE?
    A. The Product Information Sheet provided with each EasySep™ kit contains detailed staining information.
  • Q. CAN EASYSEP™ SEPARATIONS BE AUTOMATED?
    A. Yes. RoboSep™, the fully automated cell separator, automates all EasySep™ labeling and cell separation steps.
  • Q. CAN EASYSEP™ BE USED TO ISOLATE RARE CELLS?
    A. Yes. We recommend a cell concentration of 2x10⁸ cells/mL and a minimum working volume of 100 µL. Samples containing 2x10⁷ cells or fewer should be suspended in 100 µL of buffer.
  
  EASYSEP™ MAGNETIC PARTICLES
  
  
  • Q. ARE THE EASYSEP™ MAGNETIC PARTICLES FACS-COMPATIBLE?
    A. Yes, the EasySep™ particles are flow cytometry-compatible, as they are very uniform in size and about 5000X smaller than other commercially available magnetic beads used with column-free systems.
  • Q. CAN THE EASYSEP™ MAGNETIC PARTICLES BE REMOVED AFTER ENRICHMENT?
    A. No, but due to the small size of these particles, they will not interfere with downstream applications.
  • Q. HOW DOES THE BINDING OF THE EASYSEP™ MAGNETIC PARTICLE AFFECT THE CELLS? IS THE FUNCTION OF POSITIVELY SELECTED CELLS ALTERED BY THE BOUND PARTICLES?
    A. Hundreds of publications have used cells selected with EasySep™ positive selection kits for functional studies. Our in-house experiments also confirm that selected cells are not functionally altered by the EasySep™ magnetic particles.
    
    If particle binding is a key concern, we offer two options for negative selection. The EasySep™ negative selection kits can isolate untouched cells with comparable purities, while RosetteSep™ can isolate untouched cells directly from whole blood without using particles or magnets.
  
  MODIFYING THE EASYSEP™ PROTOCOL
  
  
  • Q. CAN I ALTER THE SEPARATION TIME IN THE MAGNET?
    A. Yes; however, this may impact the kit's performance. The provided EasySep™ protocols have already been optimized to balance purity, recovery and time spent on the isolation.
  • Q. FOR POSITIVE SELECTION, CAN I PERFORM MORE THAN 3 SEPARATIONS TO INCREASE PURITY?
    A. Yes, the purity of targeted cells will increase with additional rounds of separations; however, cell recovery will decrease.

This product has been used in:

1. Daniel O Griffin et al. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70-.J Exp Med 208 (1) 67-80 (January 17, 2011)
2. Leslie J Marshall et al. Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter/enhancer of JC virus and supports viral activity.J Gen Virol 91 (Pt 12) 3042-3052 (December 2010)
3. Ikbal Fathallah et al. EBV latent membrane protein 1 is a negative regulator of TLR9.J Immunol 185 (11) 6439-6447 (December 1, 2010)
4. Mark D Hicar et al. Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV.J Acquir Immune Defic Syndr 54 (3) 223-235 (July 1, 2010)
5. Nicholas J Megjugorac et al. IL-4 enhances IFN-lambda1 (IL-29) production by plasmacytoid DCs via monocyte secretion of IL-1Ra.Blood 115 (21) 4185-4190 (May 27, 2010)
6. Agnes Doreau et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosusNat Immunol 10 (7) 778-785 (July 2009)
7. Nicholas Watkins et al. A HaemAtlas: characterizing gene expression in differentiated human blood cells.Blood 113 (19) e1-9 (May 7, 2009)
8. Crescent R Isham et al. Chaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress.Blood 109 (6) 2579-2588 (March 15, 2007)
9. Kfir Oved et al. A novel postpriming regulatory check point of effector/memory T cells dictated through antigen density threshold-dependent anergy.J Immunol 178 (4) 2307-2317 (February 15, 2007)
10. Jian Li et al. Human antibodies for immunotherapy development generated via a human B cell hybridoma technology.Proc Natl Acad Sci U S A 103 (10) 3557-3562 (March 7, 2006)

FACS Histogram Results with EasySep® CD19+ Positive Selection Kit

Typical EasySep® Procedure for Human Cells